IBM & Nvidia (NVDA) Unleash Game-Changing AI System: Smarter Data, Faster Decisions
Big Blue and the chip giant just dropped a data-wrangling AI beast—Wall Street's already pricing in the hype.
Cutting through the noise
Forget clunky databases. The new system organizes chaotic information streams like a caffeinated librarian on Adderall—finally making 'big data' deliver on its decade-old promise.
Why traders should care
Faster insights mean quicker trades. NVDA's stock will likely pop on the news, because nothing excites markets like two tech titans slapping 'AI' on a press release. Meanwhile, actual productivity gains? That'll take quarters—if they materialize at all.
The bottom line
Another 'transformative' solution searching for problems. But hey—at least the algorithms will finally understand your chaotic Notes app.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
IBM Fusion does this by constantly processing and sorting data, which helps AI understand and respond better. It also works with Nvidia’s NeMo tools, which allow the AI to retrieve relevant information quickly. In addition, the system runs on IBM’s own secure servers, which means that user data doesn’t touch Google (GOOGL) or outside infrastructure. At UT Southwestern, this setup is being used to boost research and support AI tools for things like drug discovery and training future doctors.
For example, researchers can use IBM Fusion and Nvidia’s BioNeMo tools to develop new medicines faster. Medical students can also train with AI-created “patient avatars” that simulate real-life health cases, thereby helping them learn diagnoses in a more interactive way. Another tool, called Helixa AI, helps researchers work more efficiently by offering smart suggestions based on their data. IBM says that the system makes it easier for researchers to access and use their data without dealing with technical obstacles.
Is IBM a Buy, Sell, or Hold?
Turning to Wall Street, analysts have a Moderate Buy consensus rating on IBM stock based on seven Buys, six Holds, and one Sell assigned in the past three months, as indicated by the graphic below. Furthermore, the average IBM price target of $295.18 per share implies 4.8% downside risk.
